Molecular and functional characterization of cynomolgus monkey IgG subclasses

Area of Science:

• Immunology
• Primate immunology
• Antibody engineering

Background:

• Humoral immune responses in cynomolgus monkeys (cynos) significantly influence vaccine and therapeutic antibody development.
• Characterizing cyno IgG subclasses and their Fc receptor interactions is vital for understanding immunomodulatory effects and interpreting preclinical data.
• Limited information exists on cyno IgG subclass structure, function, and comparison to human IgG subclasses in Fc-dependent effector functions.

Purpose of the Study:

• To analyze the functional characteristics of cyno IgG subclasses.
• To compare the sequence features and Fc-dependent effector functions of cyno IgG subclasses with those of rhesus monkey and human IgG.
• To provide insights into the interpretation of preclinical data for human IgG therapeutics in cynos.

Main Methods:

• Cloned four cyno IgG C regions (cyIGG1, cyIGG2, cyIGG3, cyIGG4) based on sequence similarity to other primate IgGs.
• Constructed chimeric antibodies using the cloned cyno IgG C regions.
• Assessed Fc-dependent effector functions of cyno IgG subclasses in vitro using binding and functional assays.
• Compared sequence features of cyno IgG subclasses with rhesus monkey and human IgG.

Main Results:

• Rhesus monkey and cyno IgG C regions are highly conserved, with notable differences in hinge and hinge-proximal CH2 regions.
• Cyno IgG subclasses demonstrated distinctive Fc-dependent effector functions in vitro.
• Human IgG1 showed lower potency in cyno Fc receptor (FcγR) binding and effector functions compared to cyno IgG1.

Conclusions:

• Cyno IgG subclasses possess unique functional properties that differ from human IgG subclasses.
• The distinct Fc-dependent effector functions of cyno IgG subclasses necessitate careful interpretation of preclinical data derived from human IgG therapeutics in cynos.
• Further research into cyno IgG subclasses can enhance the development and assessment of vaccines and antibody-based therapeutics.